scholarly journals Clinical significance of serum mir-21,ca153 and cea in breast cancer

2021 ◽  
Vol 11 (1) ◽  
pp. 33-37
Author(s):  
Ali Rostam
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Real Time Pcr ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Established Tumor ◽  
Qualitative Detection ◽  
Potential Indicator ◽  
Circulating Levels ◽  
Higher Sensitivity

The Objective: one of the essential regulators of carcinogenesis is MicroRNA-21 (miR-21). Yet little light has been shed on its effectiveness as a tumor marker compared to the conventional ones. Comparing the diagnostic value of established tumor markers in breast cancer (BC) such as carcinoembryonic antigen (CEA) and CA153 with circulating level of miR-21 is the aim of this study.Methods:The study included 89 BC patients. Amplification of the circulating levels of miR-21 and miR-16 done using real-time PCR qualitative detection, while electrochemiluminescence assays was used to detect circulating levels of CEA and CA153. The diagnostic sensitivity for BC was compared between the three.Results: The serum miR-21 levels were high significantly BC patients, as the latter had much higher levels (P<0.001). the CA153 and CEA sensitivities were 15.73% and 22.47% respectively, while miR-21 Sensitivity and specificity were 87.6% and 87.3%.Conclusion:in BC patients miR-21 exhibits far higher sensitivity for diagnoses than both CEA and CA153. Thus especially in the early stages of BC, miR-21 can become a potential indicator for diagnosis, albeit the clinical stage, PR and ER statuses were not correlated in this study.

scholarly journals Assessing Determinants of the Current Account Deficit: A case study of India

2021 ◽  
Vol 11 (1) ◽  
pp. 23-32
Author(s):  
Jamshed Haidery ◽  
Zabihullah Shokuri
Keyword(s):  
Breast Cancer ◽  
Current Account Deficit ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Established Tumor ◽  
Qualitative Detection ◽  
Potential Indicator ◽  
Circulating Levels ◽  
Higher Sensitivity

The Objective: one of the essential regulators of carcinogenesis is MicroRNA-21 (miR-21). Yet little light has been shed on its effectiveness as a tumor marker compared to the conventional ones. Comparing the diagnostic value of established tumor markers in breast cancer (BC) such as carcinoembryonic antigen (CEA) and CA153 with circulating level of miR-21 is the aim of this study.Methods:The study included 89 BC patients. Amplification of the circulating levels of miR-21 and miR-16 done using real-time PCR qualitative detection, while electrochemiluminescence assays was used to detect circulating levels of CEA and CA153. The diagnostic sensitivity for BC was compared between the three.Results: the serum miR-21 levels were high significantly BC patients, as the latter had much higher levels (P<0.001). the CA153 and CEA sensitivities were 15.73% and 22.47% respectively, while miR-21 Sensitivity and specificity were 87.6% and 87.3%.Conclusion:in BC patients miR-21 exhibits far higher sensitivity for diagnoses than both CEA and CA153. Thus especially in the early stages of BC, miR-21 can become a potential indicator for diagnosis, albeit the clinical stage, PR and ER statuses were not correlated in this study.

scholarly journals MicroRNA-411 represents an innovative bio-marker in breast cancer detection

2020 ◽  
Author(s):  
Shuangqing Cao ◽  
Lei Zheng
Keyword(s):  
Breast Cancer ◽  
Serum Level ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Histological Grade ◽  
Clinical Stage ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Breast Cancer Patients

Abstract Background: MicroRNA-411 (MiR-411) has been reported to play an important role in tumorigenesis. This study was aimed to investigate the diagnostic performance of serum miR-411 in breast cancer.Methods: The serum level of miR-411 was determined in breast cancer patients using quantitative real-time PCR (qRT-PCR). Chi-square was applied to evaluate the association between miR-411 expression and clinical characteristics. The diagnostic value of serum miR-411 for breast cancer was estimated using receiver operator characteristic (ROC) analysis.Results: Serum miR-411 in patients with breast cancer was markedly decreased compared with healthy controls (P < 0.001). The level of miR-411 was correlated with clinical stage (P = 0.019), histological grade (P = 0.014), and lymph node metastasis (P = 0.036). ROC curve showed that serum level of miR-411 could discriminate between breast cancer patients and healthy controls, with the AUC of 0.796, combing with the sensitivity of 82.1% and the specificity of 83.2%. The cut-off value of miR-411 for breast cancer diagnosis was 1.245.Conclusions: MiR-411 plays inhibitory roles in aggressive progression of breast cancer. Serum miR-411 may be a potential non-invasive biomarker for breast cancer diagnosis.

scholarly journals DNAJC3-AS1 Is Associated with Proliferation, Metastasis, and Poor Prognosis of Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Yi Zhang ◽  
Jing-jing Li ◽  
Bo Luo ◽  
Xiao-fei Guo ◽  
Jian-xin Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Noncoding Rna ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Diagnostic Value ◽  
Normal Breast ◽  
Free Survival ◽  
Diagnostic Assays ◽  
Related Proteins ◽  
Disease Free

Objective. Long noncoding RNA DNAJC3-AS1 (DNAJC3-AS1) was a newly identified tumor-related lncRNA. The aim of the present study was to explore the prognostic value and diagnostic of DNAJC3-AS1 (DNAJC3-AS1) expression in breast cancer (BC) patients. Patients and Methods. The expression of DNAJC3-AS1 was detected in 170 BC tissues and matched normal breast samples by qRT-PCR. The diagnostic value of DNAJC3-AS1 was examined by receiver-operating characteristic (ROC) assays. The correlation of DNAJC3-AS1 with clinicopathological features and prognosis was also statistically analyzed. CCK-8 assays, colony formation assays, and Transwell assays were applied to examine the potential function of DNAJC3-AS1 on tumor progression. Western blot was used to examine the expression of EMT-related proteins. Results. The expression of DNAJC3-AS1 in BC specimens was higher than that in the adjacent nontumor tissues ( p < 0.01 ). Diagnostic assays revealed that DNAJC3-AS1 has considerable diagnostic accuracy, with an area under the ROC curve (AUC) of 0.7457 ( p < 0.001 ). High DNAJC3-AS1 expression was positively associated with lymph node metastasis ( p = 0.010 ) and clinical stage ( p = 0.023 ). A survival study revealed that patients with high DNAJC3-AS1 expression had shorter overall survival ( p = 0.0067 ) and disease-free survival ( p < 0.0001 ) than those with low DNAJC3-AS1 expression. More importantly, multivariate assays indicated that DNAJC3-AS1 was an independent prognostic factor in BC patients. Functional assays confirmed that silence of DNAJC3-AS1 distinctly suppressed the proliferation, metastasis, and EMT progress of BC cells. Conclusions. DNAJC3-AS1 may be a prognostic and diagnostic biomarker for BC patients.

Optimizing Breast Cancer Follow-up Care: Diagnostic Value and Costs of Additional Routine Breast Ultrasound

2010 ◽  
Vol 31 (S 01) ◽  
Author(s):  
S Wojcinski ◽  
A Farrokh ◽  
U Hille ◽  
E Hirschauer ◽  
W Schmidt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Value ◽  
Breast Ultrasound ◽  
Follow Up Care

Positron emission mammography in the diagnosis of breast cancer

2016 ◽  
Vol 55 (01) ◽  
pp. 15-20 ◽  
Author(s):  
J. Farahati ◽  
A. G. Müller ◽  
E. Gillman ◽  
M. Hentschel ◽  
F. H. H. Müller
Keyword(s):  
Breast Cancer ◽  
High Specificity ◽  
Diagnostic Value ◽  
Glandular Tissue ◽  
Breast Cancer Patients ◽  
Malignant Tumours ◽  
Benign Lesions ◽  
Interventional Study ◽  
Positron Emission Mammography ◽  
Positron Emission

SummaryAim: To evaluate the diagnostic value (sensitivity, specificity) of positron emission mammography (PEM) in a single site non-interventional study using the maximum PEM uptake value (PUVmax). Patients, methods: In a singlesite, non-interventional study, 108 patients (107 women, 1 man) with a total of 151 suspected lesions were scanned with a PEM Flex Solo II (Naviscan) at 90 min p.i. with 3.5 MBq 18F-FDG per kg of body weight. In this ROI(region of interest)-based analysis, maximum PEM uptake value (PUV) was determined in lesions, tumours (PUVmaxtumour), benign lesions (PUVmaxnormal breast) and also in healthy tissues on the contralateral side (PUVmaxcontralateral breast). These values were compared and contrasted. In addition, the ratios of PUVmaxtumour / PUVmaxcontralateral breast and PUVmaxnormal breast / PUVmaxcontralateral breast were compared. The image data were interpreted independently by two experienced nuclear medicine physicians and compared with histology in cases of suspected carcinoma. Results: Based on a criteria of PUV>1.9, 31 out of 151 lesions in the patient cohort were found to be malignant (21%). A mean PUVmaxtumour of 3.78 ± 2.47 was identified in malignant tumours, while a mean PUVmaxnormal breast of 1.17 ± 0.37 was reported in the glandular tissue of the healthy breast, with the difference being statistically significant (p < 0.001). Similarly, the mean ratio between tumour and healthy glandular tissue in breast cancer patients (3.15 ± 1.58) was found to be significantly higher than the ratio for benign lesions (1.17 ± 0.41, p < 0.001). Conclusion: PEM is capable of differentiating breast tumours from benign lesions with 100% sensitivity along with a high specificity of 96%, when a threshold of PUVmax >1.9 is applied.

Sign in / Sign up

Export Citation Format

Share Document